GE HealthCare Clocks $5B In Q4 Sales On Strong End Market Demand, Reaffirms Annual Guidance

Newly separated GE HealthCare Technologies Inc (NASDAQ:GEHC) has reported Q4 FY22 sales of $4.9 billion, up 8% Y/Y and 13% on an Organic basis, driven by growth in Imaging, Patient Care Solutions (PCS), and Ultrasound.
Acquisitions favorably impacted total revenue growth by 1%, and foreign exchange negatively impacted growth by 6%.
Net income was $554 million versus $564 million for the prior year, and Adjusted EBIT was $844 million versus $827 million.
Also Read: With GE Healthcare About To Start Trading, Investors Turn Cautious On Power Business Spin-Off.
The company posted an adjusted EPS of $1.31, compared to $1.36 in the prior year.
Cash flow from operating activities was $1.1 billion, up $1.1 billion year-over-year, and Free cash flow was $987 million, up $436 million year-over-year, with improvement in supply chain and collections.
Guidance: GE HealthCare expects FY23 organic revenue growth of 5%-7% year-over-year. It sees an adjusted EBIT margin of 15%-15.5%.
The company forecasts adjusted EPS of $3.60 to $3.75.
Price Action: GEHC shares are down 1.90% at $68.75 during the premarket session on the last check Monday.